Compare VOC & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VOC | ENTX |
|---|---|---|
| Founded | 2010 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.0M | 62.6M |
| IPO Year | N/A | 2015 |
| Metric | VOC | ENTX |
|---|---|---|
| Price | $3.13 | $1.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | ★ 103.2K | 102.7K |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | ★ 12.46% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.07 |
| Revenue | N/A | ★ $42,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $6.00 | $17.64 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.60 | $0.91 |
| 52 Week High | $3.84 | $3.22 |
| Indicator | VOC | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.12 | 50.19 |
| Support Level | $2.69 | $1.17 |
| Resistance Level | $3.31 | $1.37 |
| Average True Range (ATR) | 0.14 | 0.09 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 21.52 | 50.00 |
VOC Energy Trust is a statutory trust. It is created to acquire and hold a term net profits interest for the benefit of the Trust unitholders. The underlying properties include VOC Brazos' net interests which are located in the states of Kansas and Texas. The trust is entitled to receive the net proceeds from the sale of production of oil and natural gas attributable to the underlying properties. The business and affairs of the Trust are managed by the Trustee, and neither VOC Brazos nor any of its affiliates has the ability to manage or influence the operations of the Trust. It operates in a single operating and reportable segment.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.